Voyager's Alzheimer's Gene Therapy Shows 75% Tau Reduction, Trial Start H2 2026
VYGR sits 20% above its 52-week low of $2.884.
Summary
Voyager's VY1706, a gene therapy for Alzheimer's, achieved up to 75% tau protein reduction in non-human primates over six months with a favorable safety profile. This builds on the three-month data from May and the FDA's IND clearance in June. The company expects to begin dosing patients in a clinical trial in the second half of 2026. The durable tau knockdown and clean safety data strengthen the case for a one-time IV treatment targeting a key Alzheimer's pathology. With a $208M market cap, positive clinical entry could significantly re-rate the stock.
At the time of this announcement, VYGR was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.8M. The 52-week trading range was $2.88 to $5.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.